Efficient Molecular Docking for Hit Discovery on EGFR Tyrosine Kinase Inhibitors of Non-Small Cell Lung Cancer
碩士 === 高雄醫學大學 === 醫學研究所碩士班 === 105 === Epidermal growth factor receptor (EGFR), also known as Her1, is a transmembrane receptor including tyrosine kinase domain. EGFR binds with EGF ligands and then activates AKT or ERK signaling, which regulates the cellular proliferation, differentiation and mobil...
Main Authors: | Wei-Chen Lin, 林瑋辰 |
---|---|
Other Authors: | Ying-Ting Lin |
Format: | Others |
Language: | zh-TW |
Published: |
2017
|
Online Access: | http://ndltd.ncl.edu.tw/handle/55666253135273359100 |
Similar Items
-
Design and Discovery of 3rd Generation EGFR Tyrosine Kinase Inhibitors
by: Hsueh, Chin, et al.
Published: (2018) -
Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01) -
Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Gergis, Carol
Published: (2019) -
Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2
by: Frangky Sangande, et al.
Published: (2020-10-01) -
Mechanisms of Acquired Resisitance to EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Hongjie LI, et al.
Published: (2009-12-01)